Stockscreener 앱 받기
54.51
1.14%
-0.63
시장 영업 전:
53.70
-0.81
-1.49%
전일 마감가:
$55.14
열려 있는:
$55.11
하루 거래량:
1.24M
Relative Volume:
1.19
시가총액:
$3.86B
수익:
-
순이익/손실:
$-141.43M
주가수익비율:
-22.18
EPS:
-2.4581
순현금흐름:
$-226.41M
1주 성능:
+1.93%
1개월 성능:
-6.37%
6개월 성능:
+81.28%
1년 성능:
+262.19%
1일 변동 폭
$52.63
$55.70
1주일 범위
$50.23
$57.23
52주 변동 폭
$15.00
$94.90
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
명칭
Structure Therapeutics Inc Adr
전화
(650) 457-1978
주소
601 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO
Compare GPCR vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
54.51 | 3.86B | 0 | -141.43M | -226.41M | -2.4581 |
VRTX
Vertex Pharmaceuticals Inc
|
436.27 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
748.87 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
799.65 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
322.11 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
309.66 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-26 | 개시 | Wolfe Research | Peer Perform |
| 2025-05-02 | 개시 | Citigroup | Buy |
| 2025-02-28 | 개시 | William Blair | Outperform |
| 2025-01-08 | 개시 | Stifel | Buy |
| 2024-12-04 | 개시 | H.C. Wainwright | Buy |
| 2024-09-23 | 개시 | Morgan Stanley | Overweight |
| 2024-05-21 | 개시 | JP Morgan | Overweight |
| 2024-04-09 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-19 | 개시 | JMP Securities | Mkt Outperform |
| 2023-07-27 | 개시 | Piper Sandler | Overweight |
| 2023-05-25 | 재개 | Jefferies | Buy |
| 2023-02-28 | 개시 | BMO Capital Markets | Outperform |
| 2023-02-28 | 개시 | Guggenheim | Buy |
| 2023-02-28 | 개시 | Jefferies | Buy |
| 2023-02-28 | 개시 | SVB Securities | Outperform |
모두보기
Structure Therapeutics Inc Adr 주식(GPCR)의 최신 뉴스
Behavioral Patterns of GPCR and Institutional Flows - Stock Traders Daily
Why Structure Therapeutics Stock Is Suddenly Sinking - TipRanks
GPCR Technical Analysis | Trend, Signals & Chart Patterns | STRUCTURE THERAPEUTICS INC (NASDAQ:GPCR) - ChartMill
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Why Structure Therapeutics Shares Are Sliding Today - TipRanks
Aberdeen Group plc Sells 322,000 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Why Structure Therapeutics Stock Suddenly Took Off Today - TipRanks
Capricorn Fund Managers Ltd Invests $17.57 Million in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Why Structure Therapeutics (GPCR) Is Up 21.7% After Promising Phase 2 Oral Obesity Drug Data - Sahm
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Why Structure Therapeutics Stock Is Suddenly Surging - TipRanks
Structure Therapeutics (NASDAQ:GPCR) Stock Price Up 10.8%What's Next? - MarketBeat
LLY Stock Up on GLP-1 Pill Approval: Can it Outpace NVO's Wegovy Pill? - TradingView — Track All Markets
Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (TVRD) and Forte Biosciences (FBRX) - The Globe and Mail
Exchange Traded Concepts LLC Sells 32,241 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Lilly gains after FDA approves weight-loss pill, sizing down investor doubts - Sahm
Structure Therapeutics Stock Jumps on Obesity Drug Buzz - TipRanks
Structure Therapeutics Shares Surge on Obesity Drug Breakthrough - TipRanks
Structure Therapeutics (GPCR) Is Down 5.5% After Strong Oral GLP-1 Phase 2 DataWhat's Changed - Sahm
Structure Therapeutics (NASDAQ:GPCR) Stock Rating Lowered by Wall Street Zen - MarketBeat
Structure Therapeutics Obesity Trial Success Puts Valuation Gap In Focus - Sahm
Structure Therapeutics (NASDAQ:GPCR) Coverage Initiated by Analysts at Wolfe Research - MarketBeat
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Alnylam Pharma (ALNY) and Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
Wolfe Research initiates Structure Therapeutics stock rating at Peerperform By Investing.com - Investing.com India
Wolfe Research initiates Structure Therapeutics stock rating at Peerperform - Investing.com
GPCR SEC FilingsStructure Therapeutics Inc ADR 10-K, 10-Q, 8-K Forms - Stock Titan
Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (IDYA) and Incyte (INCY) - The Globe and Mail
Structure Therapeutics (NASDAQ: GPCR) awards new options and RSUs - Stock Titan
Structure Therapeutics (GPCR) CMO receives new stock options and RSU grants - Stock Titan
Structure Therapeutics (GPCR) CTO awarded options and 32,526 RSUs - Stock Titan
Structure Therapeutics (GPCR) grants CSO new stock options and RSUs - Stock Titan
Structure Therapeutics (GPCR) CFO receives large option and RSU grants - Stock Titan
Structure Therapeutics (NASDAQ: GPCR) CEO awarded new options and 260,217 RSUs - Stock Titan
NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now? - Yahoo Finance
Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges - AOL.com
B Group Acquires 4.62% Portfolio Stake in Structure Therapeutics | 2025 InvestmentNews and Statistics - IndexBox
LifeSci Capital Keeps Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Annexon Biosciences (ANNX) and Electrocore (ECOR) - The Globe and Mail
Experience real-time quotes, in-depth charts, and analyst ratings - webull.com
Did Positive Phase 2 Aleniglipron Data Just Shift Structure Therapeutics' (GPCR) Investment Narrative? - Sahm
How (GPCR) Movements Inform Risk Allocation Models - Stock Traders Daily
Structure Therapeutics (NASDAQ:GPCR) Shares Down 7.5%Should You Sell? - MarketBeat
Why Structure Therapeutics Shares Are Tumbling Today - TipRanks
Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Structure Therapeutics, Inc. Sponsored ADR (GPCR) and Lifecore Biomedical (LFCR) - The Globe and Mail
What is HC Wainwright's Forecast for GPCR FY2027 Earnings? - MarketBeat
Analysts Offer Insights on Healthcare Companies: Merit Medical Systems (MMSI), Voyager Therapeutics (VYGR) and Structure Therapeutics, Inc. Sponsored ADR (GPCR) - The Globe and Mail
Structure Therapeutics Posts 15%+ Weight Loss in ACCESS II for Oral GLP-1 Aleniglipron, Eyes Phase III - MarketBeat
Buy Rating on GPCR Driven by Competitive Aleniglipron Phase 2b Efficacy and Clear Path to Phase 3 in Obesity - TipRanks
Structure Therapeutics Inc Adr (GPCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.95%
3.83%
자본화:
|
볼륨(24시간):